ATE471720T1 - Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73 - Google Patents

Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73

Info

Publication number
ATE471720T1
ATE471720T1 AT04721913T AT04721913T ATE471720T1 AT E471720 T1 ATE471720 T1 AT E471720T1 AT 04721913 T AT04721913 T AT 04721913T AT 04721913 T AT04721913 T AT 04721913T AT E471720 T1 ATE471720 T1 AT E471720T1
Authority
AT
Austria
Prior art keywords
cytokine
induced expression
adenosine levels
increasing adenosine
increasing
Prior art date
Application number
AT04721913T
Other languages
English (en)
Inventor
Sirpa Jalkanen
Original Assignee
Faron Pharmaceuticals Oy
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FI20030467A external-priority patent/FI20030467A0/fi
Application filed by Faron Pharmaceuticals Oy filed Critical Faron Pharmaceuticals Oy
Application granted granted Critical
Publication of ATE471720T1 publication Critical patent/ATE471720T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
AT04721913T 2003-03-28 2004-03-19 Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73 ATE471720T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FI20030467A FI20030467A0 (fi) 2003-03-28 2003-03-28 Menetelmä tulehdustilojen hoitamiseen
US51542503P 2003-10-30 2003-10-30
PCT/FI2004/000158 WO2004084933A1 (en) 2003-03-28 2004-03-19 Elevation of adenosine level by cytokine-induced expression of cd73

Publications (1)

Publication Number Publication Date
ATE471720T1 true ATE471720T1 (de) 2010-07-15

Family

ID=33099764

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04721913T ATE471720T1 (de) 2003-03-28 2004-03-19 Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73

Country Status (9)

Country Link
US (3) US7534423B2 (de)
EP (1) EP1608400B1 (de)
JP (1) JP2011225607A (de)
AT (1) ATE471720T1 (de)
CA (1) CA2519465C (de)
CY (1) CY1111215T1 (de)
DE (1) DE602004027797D1 (de)
PL (1) PL1608400T3 (de)
WO (1) WO2004084933A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070160645A1 (en) * 2001-10-25 2007-07-12 Jakob Vinten-Johansen PostConditioning System And Method For The Reduction Of Ischemic-Reperfusion Injury In The Heart And Other Organs
WO2003035142A2 (en) 2001-10-25 2003-05-01 Emory University Catheter for modified perfusion
US7534423B2 (en) 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual
CA2592142A1 (en) * 2004-12-22 2006-06-29 Emory University Therapeutic adjuncts to enhance the organ protective effects of postconditioning
FI20051003A0 (fi) 2005-10-07 2005-10-07 Faron Pharmaceuticals Oy Menetelmä iskemiareperfuusiovaurion tai monielinhäiriön hoitamiseksi tai estämiseksi
US8975081B2 (en) 2007-10-24 2015-03-10 Faron Pharmaceuticals Oy Biomarker for monitoring development of diseases and assessing the efficacy of therapies
FI20070795A0 (fi) 2007-10-24 2007-10-24 Faron Pharmaceuticals Oy Uusi biomarkkeri sairauksien kehittämisen tarkkailuun ja terapioiden tehon arviointiin
US20090130092A1 (en) 2007-10-30 2009-05-21 Pinsky David J Nucleotide phosphate dissipation as a treatment for vascular disorders
WO2009106368A1 (en) * 2008-02-29 2009-09-03 Gelato Corporation N.V. Method for increasing the activity of the immune system of a mammal at risk of inflammatory diseases
EP2274007B1 (de) 2008-03-10 2016-12-14 Cornell University Modulation der durchlässigkeit der blut-hirn-schranke
CA2772204A1 (en) 2009-08-31 2011-03-03 Amplimmune, Inc. Methods and compositions for the inhibition of transplant rejection
AU2011272941B2 (en) 2010-06-30 2014-05-29 Compugen Ltd. C10RF32 for the treatment of multiple sclerosis, rheumatoid arthritis and other autoimmune disorders
CU23963B1 (es) * 2011-07-01 2013-12-11 Ct De Ingeniería Genética Y Biotecnología Composiciones farmacéuticas a partir de derivados de la c-ficocianina y combinaciones con interferones del tipo i para el tratamiento de enfermedades cerebrales isquémicas y neurodegenerativas
US20140234373A1 (en) 2011-09-16 2014-08-21 Georfia Regents University Methods of Promoting Immune Tolerance
US10531655B2 (en) 2011-12-02 2020-01-14 The Regents Of The University Of California Reperfusion protection solution and uses thereof
CA2894879A1 (en) 2012-12-19 2014-06-26 Amplimmune, Inc. B7-h4 specific antibodies, and compositions and methods of use thereof
US10864170B2 (en) 2015-09-04 2020-12-15 Yale University Polymeric bile acid nanocompositions targeting the pancreas and colon
FI126979B (en) 2016-02-29 2017-09-15 Faron Pharmaceuticals Oy Lyophilized pharmaceutical formulation and its use
WO2017155981A1 (en) 2016-03-07 2017-09-14 Massachusetts Institute Of Technology Protein-chaperoned t-cell vaccines
US20190117799A1 (en) 2016-04-01 2019-04-25 The Brigham And Women's Hospital, Inc. Stimuli-responsive nanoparticles for biomedical applications
US12084495B2 (en) 2016-08-03 2024-09-10 Nextcure, Inc. Compositions and methods for modulating LAIR signal transduction
DK3515478T3 (da) 2016-09-21 2024-05-21 Nextcure Inc Antistoffer til SIGLEC-15 og fremgangsmåder til anvendelse deraf
EP4360714A3 (de) 2016-09-21 2024-07-24 Nextcure, Inc. Antikörper für siglec-15 und verfahren zur verwendung davon
MX2020002611A (es) 2017-09-07 2020-07-13 Univ Res Inst Inc Augusta Activador especifico de akt3 y usos del mismo.
US20200077906A1 (en) 2018-09-07 2020-03-12 Augusta University Research Institute, Inc. Method and System for Monitoring Brain Function and Intracranial Pressure
CN119700703A (zh) 2019-01-17 2025-03-28 佐治亚技术研究公司 含有氧化的胆固醇的药物递送系统
AU2021266786A1 (en) 2020-05-08 2022-12-15 Georgiamune, Inc. Akt3 modulators

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0835661B1 (de) * 1985-10-14 2007-08-29 Yeda Research And Development Co. Ltd. Menschlisches Interferon-Beta 2A zur Verwendung als Arzneimittel
GB9702021D0 (en) 1997-01-31 1997-03-19 Imperial College Medicaments
EP1221976A4 (de) * 1999-09-28 2003-12-03 Amarillo Biosciences Inc Ifn-gama in niedriger dosierung zur behandlung von erkrankungen
DE60129472T2 (de) * 2001-04-03 2008-04-17 U-Cytech B.V. Behandlung von hypoxya/ischaemia blutflusswiderstand mit beta-interferon
AU2002310922A1 (en) 2001-05-04 2002-11-18 Institute Of Molecular And Cell Biology Interferons in the treatment of ischemia
US6911198B2 (en) 2001-09-17 2005-06-28 Yeda Research And Development Co. Ltd. Method and pharmaceutical composition for treating inflammation
US20060083715A1 (en) 2002-03-12 2006-04-20 Steven Glazer Interferon beta-like molecules for treatment of stroke
US7534423B2 (en) * 2003-03-28 2009-05-19 Faron Pharmaceuticals Oy Method for inducing an elevated level of adenosine in an individual

Also Published As

Publication number Publication date
US7727521B2 (en) 2010-06-01
DE602004027797D1 (de) 2010-08-05
US7534423B2 (en) 2009-05-19
CA2519465C (en) 2016-08-02
EP1608400A1 (de) 2005-12-28
JP2011225607A (ja) 2011-11-10
US20060198821A1 (en) 2006-09-07
US20090269303A1 (en) 2009-10-29
WO2004084933A1 (en) 2004-10-07
EP1608400B1 (de) 2010-06-23
CA2519465A1 (en) 2004-10-07
US20060034801A1 (en) 2006-02-16
CY1111215T1 (el) 2015-06-11
PL1608400T3 (pl) 2010-11-30

Similar Documents

Publication Publication Date Title
ATE471720T1 (de) Erhöhung des adenosin-spiegels durch cytokin- induzierte expression von cd73
ATE427356T1 (de) Komplementinhibitoren aus zecken
PH12013500913A1 (en) Substituted-quinoxaline-type-piperidine compounds and the uses thereof
WO2006110187A3 (en) Methods and compositions for the treatment of anxiety disorders
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
BR9913319A (pt) Composições e métodos para tratamento de doenças mitocondriais
TW200716612A (en) Pyrimidine compounds
DOP2007000051A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
PA8649201A1 (es) Composiciones fungicidas
MX2009007644A (es) Compuestos de piperidina heterociclicos sustituidos y usos de los mismos.
AR060089A1 (es) Tratamiento del dolor
MXPA05000765A (es) Compuestos de 5-ariltetrazola, composiciones de los mismos y usos para los mismos.
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
DE60333901D1 (de) Verfahren zur reduzierung der angiogenese
TW200500079A (en) Compositions and methods for treating coronavirus infection and sars
BRPI0416030A (pt) pirido-7-pirimidin-7-onas substituìdas com hidroxialquila
NO20092018L (no) Fremgangsmater for a behandle depresjon
BRPI0607850A2 (pt) método para o tratamento de materiais contendo cobre
DK1965809T3 (da) Præparater til forbedring af sundhedstilstanden i dyrs tarmsystem og dyrs ydeevne omfattende Beta-glucanerne og Alfa-fucaner
CL2004000765A1 (es) Composicion farmaceutica intranasal que comprende un compuesto derivado de 8,9-dioxo-2,6-diazabiciclo.
EA201000432A1 (ru) Фунгицидные смеси тритиконазола и дифеноконазола
WO2005102296A3 (en) Combinations for the treatment of immunoproliferative skin disorders such as psoriasis
TW200742580A (en) Methods for treating nephrolithiasis
IN2015DN03331A (de)
BRPI0509667A (pt) azaquinazolinas substituìdas com eficácia antiviral

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1608400

Country of ref document: EP